Meta-analysis of relapse prevention antidepressant trials in depressive disorders

References

• Ustün TB, Ayuso-Mateos JL, Chatterji S, Mathers C, Murray CJ. Global burden of depressive disorders in the year 2000. Br J Psychiatry 2004; 184:386–392.
   PubMed Web of Science ®Google Scholar
• Anderson IM, Ferrier IN, Baldwin RC . Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol 2008; 22:343–396.
   PubMed Web of Science ®Google Scholar
• Cipriani A, Geddes JR, Furukawa TA, Barbui C. Metareview on short-term effectiveness and safety of antidepressants for depression: an evidence-based approach to inform clinical practice. Can J Psychiatr 2007; 52:553–562.
   PubMed Web of Science ®Google Scholar
• Melfi CA, Chawla AJ, Croghan TW, Hanna MP, Kennedy S, Sredl K. The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. Arch Gen Psychiatry 1998; 55:1128–1132.
   PubMed Web of Science ®Google Scholar
• Geddes JR, Carney SM, Davies C . Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 2003; 361:653–661.
   PubMed Web of Science ®Google Scholar
• Khan A, Khan SR, Walens G, Kolts R, Giller EL. Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: an analysis of the food and drug administration summary basis of approval reports. Neuropsychopharmacology 2003; 28: 552–557.
   PubMed Web of Science ®Google Scholar
• Kaymaz N, van Os J, Loonen AJ, Nolen WA. Evidence that patients with single versus recurrent depressive episodes are differentially sensitive to treatment discontinuation: a meta-analysis of placebo-controlled randomized trials. J Clin Psychiatry 2008; 69:1423–1436.
   PubMed Web of Science ®Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7:177–188.
   PubMed Web of Science ®Google Scholar
• Alexopoulos GS, Meyers BS, Young RC . Executive dysfunction and long-term outcomes of geriatric depression. Arch Gen Psychiatry 2000; 57:285–290.
   PubMed Web of Science ®Google Scholar
• Burke WJ, Hendricks SE, McArthur-Miller D . Weekly dosing of fluoxetine for the continuation phase of treatment of major depression: results of a placebo-controlled, randomized clinical trial. J Clin Psychopharmacol 2000; 20:423–427.
   PubMed Web of Science ®Google Scholar
• Doogan DP, Caillard V. Sertraline in the prevention of depression. Br J Psychiatry 1992; 160:217–222.
   PubMed Web of Science ®Google Scholar
• Emslie GJ, Kennard BD, Mayes TL . Fluoxetine versus placebo in preventing relapse of major depression in children and adolescents. Am J Psychiatry 2008; 165:459–467.
   PubMed Web of Science ®Google Scholar
• Feiger AD, Bielski RJ, Bremner J . Double-blind, placebo-substitution study of nefazodone in the prevention of relapse during continuation treatment of outpatients with major depression. Int Clin Psychopharmacol 1999; 14:19–28.
   PubMed Web of Science ®Google Scholar
• Gilaberte I, Montejo AL, de la Gandara J . Fluoxetine in the prevention of depressive recurrences: a double-blind study. J Clin Psychopharmacol 2001; 21:417–424.
   PubMed Web of Science ®Google Scholar
• Gorwood P, Weiller E, Lemming O, Katona C. Escitalopram prevents relapse in older patients with major depressive disorder. Am J Geriatr Psychiatry 2007; 15:81–93.
   Web of Science ®Google Scholar
• Hochstrasser B, Isaksen PM Koponen PM . Prophylactic effect of citalopram in unipolar, recurrent depression: placebo-controlled study of maintenance therapy. Br J Psychiatry 2001; 178:304–310.
   PubMed Web of Science ®Google Scholar
• Kamijima K, Burt T, Cohen G, Arano I, Hamasaki T. A placebo–controlled, randomized withdrawal study of sertraline for major depressive disorder in Japan. Int Clin Psychopharmacol 2006; 21:1–9.
   PubMed Web of Science ®Google Scholar
• Keller MB, Ruwe FJ, Janssens CJ, Sitsen JM, Jokinen R, Janczewski J. Relapse prevention with gepirone ER in outpatients with major depression. J Clin Psychopharmacol 2005; 25:79–84.
   PubMed Web of Science ®Google Scholar
• Keller MB, Trivedi MH, Thase ME . The prevention of recurrent episodes of depression with venlafaxine for two years (PREVENT) study: outcomes from the 2-year and combined maintenance phases. J Clin Psychiatry 2007; 68:1246–1256.
   PubMed Web of Science ®Google Scholar
• Kishimoto A, Mizukawa R, Matsuzaki F . Prophylactic effect of mianserin on recurrent depression. Acta Psychiatr Scand 1994; 89:46–51.
   PubMed Web of Science ®Google Scholar
• Klysner R, Bent-Hansen J, Hansen HL . Efficacy of citalopram in the prevention of recurrent depression in elderly patients: placebo-controlled study of maintenance therapy. Br J Psychiatry 2002; 181:29–35.
   PubMed Web of Science ®Google Scholar
• Kornstein SG, Bose A, Li D, Saikali KG, Gandhi C. Escitalopram maintenance treatment for prevention of recurrent depression: a randomized, placebo-controlled trial. J Clin Psychiatry 2006; 67:1767–1775.
   PubMed Web of Science ®Google Scholar
• Lustman PJ, Clouse RE, Nix BD . Sertraline for prevention of depression recurrence in diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry 2006; 63: 521–529.
   PubMed Web of Science ®Google Scholar
• McGrath PJ, Stewart JW, Quitkin FM . Predictors of relapse in a prospective study of fluoxetine treatment of major depression. Am J Psychiatry 2006; 163:1542–1548.
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Dufour H, Brion S . The prophylactic efficacy of fluoxetine in unipolar depression. Br J Psychiatry 1988; 3:S69–76.
   Google Scholar
• Montgomery SA, Rasmussen JG, Tanghoj P. A 24-week study of 20 mg citalopram, 40 mg citalopram, and placebo in the prevention of relapse of major depression. Int Clin Psychopharmacol 1993; 8:181–188.
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Entsuah R, Hackett D, Kunz NR, Rudolph RL. Venlafaxine versus placebo in the preventive treatment of recurrent major depression. J Clin Psychiatry 2004; 65:328–336.
   PubMed Web of Science ®Google Scholar
• Perahia DG, Gilaberte I, Wang F . Duloxetine in the prevention of relapse of major depressive disorder: double-blind placebo-controlled study. Br J Psychiatry 2006; 188:346–353.
   PubMed Web of Science ®Google Scholar
• Rapaport MH, Bose A, Zheng H. Escitalopram continuation treatment prevents relapse of depressive episodes. J Clin Psychiatry 2004; 65:44–49.
   PubMed Web of Science ®Google Scholar
• Robert P, Montgomery SA. Citalopram in doses of 20–60 mg is effective in depression relapse prevention: a placebo-controlled 6 month study. Int Clin Psychopharmacol 1995; 10:S29–35.
   PubMed Web of Science ®Google Scholar
• Rouillon F, Berdeaux G, JC Bisserbe . Prevention of recurrent depressive episodes with milnacipran: consequences on quality of life. J Affect Disord 2000; 58:171–180.
   PubMed Web of Science ®Google Scholar
• Rouillon F, Phillips R, Serrurier D, Ansart E, Gerard MJ. Rechutes de dépression unipolaire et efficacité de la maprotiline [Efficacy of maprotiline in relapse of unipolar depression]. Encephale 1989; 15:527–534.
   PubMedGoogle Scholar
• Schmidt ME, Fava M, Robinson JM, Judge R. The efficacy and safety of a new enteric-coated formulation of fluoxetine given once weekly during the continuation treatment of major depressive disorder. J Clin Psychiatry 2000; 61:851–857.
   PubMed Web of Science ®Google Scholar
• Simon JS, Aguiar LM, Kunz NR, Lei D. Extended-release venlafaxine in relapse prevention for patients with major depressive disorder. J Psychiatr Res 2004; 38:249–257.
   PubMed Web of Science ®Google Scholar
• Terra JL, Montgomery SA. Fluvoxamine prevents recurrence of depression: results of a long-term, double-blind, placebo-controlled study. Int Clin Psychopharmacol 1998; 13:55–62.
   PubMed Web of Science ®Google Scholar
• Thase ME, Nierenberg AA, Keller MB, Panagides J. Efficacy of mirtazapine for prevention of depressive relapse: a placebo-controlled double-blind trial of recently remitted high-risk patients. J Clin Psychiatry 2001; 62:782–788.
   PubMed Web of Science ®Google Scholar
• Versiani M, Mehilane L, Gaszner P, Arnaud CR. Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder. J Clin Psychiatry 1999; 60:400–406.
   PubMed Web of Science ®Google Scholar
• Weihs KL, Houser TL, Batey SR . Continuation phase treatment with bupropion SR effectively decreases the risk for relapse of depression. Biol Psychiatry 2002; 51:753–761.
   PubMed Web of Science ®Google Scholar
• Wilson KC, Mottram RG, Ashworth L, Abou-Saleh MT. Older community residents with depression: long-term treatment with sertraline. Randomised, double-blind, placebo-controlled study. Br J Psychiatry 2003; 182:492–497.
   PubMed Web of Science ®Google Scholar
• Amsterdam JD, Brunswick DJ, Gibertini M. Sustained efficacy of gepirone-IR in major depressive disorder: a double-blind placebo substitution trial. J Psychiatr Res 2004; 38:259–265.
   PubMed Web of Science ®Google Scholar
• Bialos D, Giller E, Jatlow P, Docherty J, Harkness L. Recurrence of depression after discontinuation of long-term amitriptyline treatment. Am J Psychiatry 1982; 139:325–329.
   PubMed Web of Science ®Google Scholar
• Cook BL, Helms PM, Smith RE, Tsai M. Unipolar depression in the elderly. Reoccurrence on discontinuation of tricyclic antidepressants. J Affect Disord 1986; 10:91–94.
   PubMed Web of Science ®Google Scholar
• Coppen A, Ghose K, Montgomery S, Rama RV, Bailey J, Jorgensen A. Continuation therapy with amitriptyline in depression. Br J Psychiatry 1978; 133:28–33.
   PubMed Web of Science ®Google Scholar
• Davidson J, Raft D. Use of phenelzine in continuation therapy. Neuropsychobiology 1984; 11:191–194.
   PubMed Web of Science ®Google Scholar
• Frank E, Kupfer DJ, Perel JM . Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1990; 47:1093–1099.
   PubMed Web of Science ®Google Scholar
• Georgotas A, McCue RE, Cooper TB. A placebo-controlled comparison of nortriptyline and phenelzine in maintenance therapy of elderly depressed patients. Arch Gen Psychiatry 1989; 46: 783–786.
   PubMed Web of Science ®Google Scholar
• Glen AI, Johnson AL, Shepherd M. Continuation therapy with lithium and amitriptyline in unipolar depressive illness: a randomized, double-blind, controlled trial. Psychol Med 1984; 14:37–50.
   PubMed Web of Science ®Google Scholar
• Jenkins SW, Robinson DS, Fabre LF. Gepirone treatment of major depression. J Clin Psychopharmacol 1990; 10:77–85.
   PubMed Web of Science ®Google Scholar
• Lendresse PH, Chen MC, LeMarie JC. Traitement prolongé par nomifensine 75mg dans les états dépressifs neurotiques et reactionnels [Sustained treatment with nomifensine 75mg in neurotic and reactive depressive states]. Psychiatrie Francaise 1985; 16: 156–158.
   Google Scholar
• Old Age Depression Interest Group. How long should the elderly take antidepressants? A double-blind placebo-controlled study of continuation/prophylaxis therapy with dothiepin. Br J Psychiatry 1993; 162:175–182.
   PubMed Web of Science ®Google Scholar
• Prien RF, Kupfer DJ, Mansky PA . Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders. Report of the NIMH Collaborative Study Group comparing lithium carbonate, imipramine, and a lithium carbonate-imipramine combination. Arch Gen Psychiatry 1984; 41:1096–1104.
   PubMed Web of Science ®Google Scholar
• Reynolds CF, Frank E, Perel JM . Nortriptyline and interpersonal psychotherapy as maintenance therapies for recurrent major depression: a randomized controlled trial in patients older than 59 years. JAMA 1999; 281:39–45.
   PubMed Web of Science ®Google Scholar
• Robinson DS, Lerfald SC, Bennett B . Continuation and maintenance treatment of major depression with the monoamine oxidase inhibitor phenelzine: a double-blind placebo-controlled discontinuation study. Psychopharmacol Bull 1991; 27:31–39.
   PubMedGoogle Scholar
• Ferreri M, Colonna L, Leger JM. Efficacy of amineptine in the prevention of relapse in unipolar depression. Int Clin Psychopharmacol 1997; 12 (supplement 3) S39–45.
   Google Scholar
• Gelenberg AJ, Trivedi MH, Rush AJ . Randomized, placebo-controlled trial of nefazodone maintenance treatment in preventing recurrence in chronic depression. Biol Psychiatry 2003; 54: 806–817.
   PubMed Web of Science ®Google Scholar
• Harrison W, Rabkin J, Stewart JW, McGrath PJ, Tricamo E, Quitkin F. Phenelzine for chronic depression: a study of continuation treatment. J Clin Psychiatry 1986; 47:346–349.
   PubMed Web of Science ®Google Scholar
• Kane JM, Quitkin FM, Rifkin A, Ramos Jr L, Nayak DD, Howard A. Lithium carbonate and imipramine in the prophylaxis of unipolar and bipolar II illness: a prospective, placebo-controlled comparison. Arch Gen Psychiatry 1982; 39:1065–1069.
   PubMed Web of Science ®Google Scholar
• Keller MB, Kocsis JH, Thase ME . Maintenance phase efficacy of sertraline for chronic depression: a randomized controlled trial. JAMA 1998; 280:1665–1672.
   PubMed Web of Science ®Google Scholar
• Kocsis JH, Friedman RA, Markowitz JC . Maintenance therapy for chronic depression. A controlled clinical trial of desipramine. Arch Gen Psychiatry 1996; 53:769–774.
   PubMed Web of Science ®Google Scholar
• Kocsis JH, Schatzberg A, Rush AJ . Psychosocial outcomes following long-term, double-blind treatment of chronic depression with sertraline vs placebo. Arch Gen Psychiatry 2002; 59:723–728.
   PubMed Web of Science ®Google Scholar
• Reimherr FW, Amsterdam JD, Quitkin FM . Optimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatment. Am J Psychiatry 1998; 155:1247–1253.
   PubMed Web of Science ®Google Scholar
• Stewart JW, Tricamo E, McGrath P, Quitkin FM. Prophylactic efficacy of phenelzine and imipramine in chronic atypical depression: likelihood of recurrence on discontinuation after 6 months’ remission. Am J Psychiatry 1997; 154:31–36.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd. DSM-III. Washington DC: American Psychiatric Association, 1980.
   Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd, revised. DSM-IIIR. Washington DC: American Psychiatric Association, 1987.
   Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th. DSM-IV. Washington DC: American Psychiatric Association, 1994.
   Google Scholar
• Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:56–62.
   PubMed Web of Science ®Google Scholar
• Guy W. ECDEU Assessment Manual for Psychopharmacology. Washington DC: US Department of Health, Education and Welfare, 1976:218–222.
   Google Scholar
• Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134:382–389.
   PubMed Web of Science ®Google Scholar
• Cipriani A, Furukawa TA, Salanti G . Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009; 373:746–758.
   PubMed Web of Science ®Google Scholar
• Walsh TB, Seidman SN, Sysko R, Gould M. Placebo response in studies of major depression: variable, substantial, and growing. JAMA 2002; 287:1840–1847.
   PubMed Web of Science ®Google Scholar
• Charney DS, Reynolds CF III, Lewis L . Depression and Bipolar Support Alliance consensus statement on the unmet needs in diagnosis and treatment of mood disorders in late life. Arch Gen Psychiatry 2003; 60:664–672.
   PubMed Web of Science ®Google Scholar